All Fulcrum Publications

December 7, 2020

In vitro characterization of FTX-6058, a novel small molecule fetal hemoglobin inducer for sickle cell disease

Billy Stuart, Pete Rahl, Kingsley Appiah, Ivan Efremov, Lorin A Thompson, Owen Wallace, Christopher Moxham

December 7, 2020

FTX-6058, a novel HbF-inducing agent for the treatment of Sickle Cell Disease and b-Thalassemia

Billy Stuart, Keqiang Xie, Mark Roth, Steven Kazmirski, Kinglsey Appiah, Richard Barnes, Qingyi Li, David Peters, Lucienne Ronco, Kim Stickland, Paul Bruno, Diego Cadavid, Lorin Thompson, Owen Wallace, Ivan Efremov, and Peter Rahl

December 7, 2020

In vivo characterization of FTX-6058, a novel small molecule fetal hemoglobin inducer for sickle cell disease

Keqiang Xie, Mark Roth, Ivan Efremov, Serena Silver, Lucienne Ronco, Lorin A Thompson, Kim Stickland, Christopher Moxham and Owen Wallace

October 1, 2020

Development and Evaluation of a Whole-body MRI Protocol and Analysis Algorithms to Measure Changes in Skeletal Muscle in FSHD

Diego Cadavid, Michelle Mellion, Shane Raines, Per Widholm, and Olof Dahlqvist Leinhard

October 1, 2020

A Biomarker of Aberrant DUX4 Activity to Evaluate Losmapimod Treatment Effect in FSHD Phase 2 Trials

Lucienne Ronco, Kathryn Wagner, Diego Cadavid, Jayashree Chadchankar, Aaron Chang, Michelle Mellion, Adefowope Odueyungbo, Shane Raines, Anugraha Raman, Alan Robertson, Alejandro Rojas, Ning Shen, Perry Shieh, Jeffrey Statland, Rabi Tawil, Stephen Tapscott, Baziel van Engelen, Leo Wang, Nick Johnson, Owen Wallace

October 1, 2020

Open-Label Pilot Study of Losmapimod in FSHD1 (NCT04004000)

Joost Kools, Nicol Voermans, Karlien Mul, Lucienne Ronco, Adefowope Odueyungbo, Venkateswarlu Kondragunta, Kelly Marshall, Mary Bylo, Michelle Mellion, Baziel van Engelen, Diego Cadavid

October 1, 2020

A Phase 2, Randomized, Placebo-Controlled, 48-Weeks Study of the Efficacy and Safety of Losmapimod in Treating Subjects with FSHD: ReDUX4 (NCT04003974)

Rabi Tawil, Kathryn Wagner, Jeffrey Statland, Leo Wang, Angela Genge , Hanns Lochmüller, Summer Gibson, Namita Goyal, Johanna Hamel, Lawrence Hayward, Nicholas Johnson, Samantha LoRusso, Jordi Díaz-Manera, Juan J Vilchez- Padilla, Alan Pestronk, Sabrina Sacconi, Perry B. Shieh, S.H.Subramony, Michelle Hage, Adefowope Odueyungbo, William Tracewell, Alisa Rahilly, L. Alejandro Rojas, Michelle Mellion, Lucienne Ronco, Diego Cadavid

October 30, 2019

Design of a biomarker of DUX4 activity to evaluate losmapimod treatment effect in FSHD Phase 2 trials

Lucienne Ronco, Diego Cadavid, Jayashree Chadchankar, Aaron Chang, Michelle Mellion, Alan Robertson, Alejandro Rojas, Ning Shen, Rabi Tawil, Stephen Tapscott, Leo Wang, Owen Wallace

October 16, 2019

Phase 1 clinical trial of losmapimodin FSHD: safety, tolerability and target engagement

Michelle L. Mellion, Lucienne Ronco, Drew Thompson, Michelle Hage, Sander Brooks, Emilie van Brummelen, Lisa Pagan, Umesh Badrising, William Tracewell, Shane Raines, Baziel van Engelen, Geert Jan Groeneveld, Diego Cadavid

October 4, 2019

Safety and tolerability of losmapimod, a selective p38a/b MAPK inhibitor, for treatment of FSHD at its root cause

Diego Cadavid, Michelle Mellion, Owen Wallace, Lucienne Ronco, Drew Thompson, Alejandro Rojas, Michelle Hage, Robert Gould